1556 related articles for article (PubMed ID: 18684703)
1. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
3. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
6. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
[TBL] [Abstract][Full Text] [Related]
8. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
[TBL] [Abstract][Full Text] [Related]
9. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
Shorr AF; Kunkel MJ; Kollef M
J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
[TBL] [Abstract][Full Text] [Related]
10. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
11. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
13. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
Rubinstein E; Cammarata S; Oliphant T; Wunderink R;
Clin Infect Dis; 2001 Feb; 32(3):402-12. PubMed ID: 11170948
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
15. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
16. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.
Mauldin PD; Salgado CD; Durkalski VL; Bosso JA
Ann Pharmacother; 2008 Mar; 42(3):317-26. PubMed ID: 18285560
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the prevalence of patients co-colonized or infected with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in China: a hospital-based study.
Wang Z; Cao B; Liu YM; Gu L; Wang C
Chin Med J (Engl); 2009 Jun; 122(11):1283-8. PubMed ID: 19567138
[TBL] [Abstract][Full Text] [Related]
18. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
19. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
20. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
